Table 3.

Treatment effects on the incidence and multiplicity of benign and preinvasive mammary lesions

Experimental groupsNo. of ratsIntraductal proliferation
MildModerateFloridDCIS
No. of lesionsNo. of rats (%)Lesions/rat (mean ± SE)No. of lesionsNo. of rats (%)Lesions/rat (mean ± SE)No. of lesionsNo. of rats (%)Lesions/rat (mean ± SE)No. of lesionsNo. of rats (%)Lesions/rat (mean ± SE)
1, 20% CO368129 (81%)2.25 ± 0.3397 (19%)0.25 ± 0.0955 (14%)0.14 ± 0.0644 (11%)0.11 ± 0.05
2, 20% CO + 100 μg/kg tamoxifen3911035 (90%)2.82 ± 0.342619 (49%)*0.67 ± 0.1355 (13%)0.13 ± 0.0532 (5%)0.08 ± 0.06
3, 17% FO3612936 (100%)*3.58 ± 0.34*2718 (50%)*0.75 ± 0.1643 (8%)0.11 ± 0.071411 (31%)0.39 ± 0.11
4, 17% FO + 100 μg/kg tamoxifen359930 (86%)2.83 ± 0.452820 (57%)0.80 ± 0.1387 (20%)0.23 ± 0.081311 (31%)0.37 ± 0.10
  • *P < 0.05 versus group 1.

  • P < 0.05 versus group 2.

  • P < 0.01 versus group 1.